Лучшие подкасты про Oncotarget (2024)

1
Impact Journals Sponsors 2024 Ride for Roswell 3:59

6d ago3:59

3:59

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay trib…

1
Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations 8:07

11d ago8:07

8:07

In the relentless battle against non-small cell lung cancer (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations, the development of resistance has long been a formidable obstacle. Historically, first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, afatinib, and dacomitinib have faced a signif…

1
Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells 3:38

12d ago3:38

3:38

BUFFALO, NY- June 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.”Histone deacetylase inhibitors (HDACi) can modulate the acetylation …

1
BTK Inhibitor-related Cardiotoxicity: Quest for Predictive Biomarkers, Improved Risk Stratification 2:29

13d ago2:29

2:29

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.”In this new perspective, researchers Jai N. Patel, Jai Singh, and Nilanjan Ghosh from Atrium Healt…

1
Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 6:46

19d ago6:46

6:46

Dr. Benoit Chabot from Université de Sherbrooke in Quebec, CA, discusses a research paper he co-authored that was published by Oncotarget in Volume 15, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”DOI - https://do…

1
The Importance of Integrated Therapies on Cancer: Silibinin, an Old and New Molecule 3:15

20d ago3:15

3:15

BUFFALO, NY- May 28, 2024 – A new review paper was published in Oncotarget's Volume 15 on May 23, 2024, entitled, “The importance of integrated therapies on cancer: Silibinin, an old and new molecule.”In this new review, researchers Elisa Roca, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra Cucinella, Giorgio Madonia, Licia Martin…

1
Combating Doxorubicin-Resistant Acute Myeloid Leukemia 10:39

25d ago10:39

10:39

Upon diagnosing acute myeloid leukemia (AML), the initial step involves assessing a patient’s eligibility for intensive chemotherapy. The standard treatment protocol for newly diagnosed AML encompasses intensive chemotherapy to achieve complete remission, followed by post-remission therapy, which may include additional chemotherapy and/or stem cell…

1
GZ17-6.02 Kills Uveal Melanoma Cells 3:53

26d ago3:53

3:53

BUFFALO, NY- May 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 17, 2024, entitled, “GZ17-6.02 kills PDX isolates of uveal melanoma.”In this new study, researchers Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent from Virginia Commonw…

1
Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response 3:19

28d ago3:19

3:19

BUFFALO, NY- May 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”The diheteroarylamide-based compound 1C8 and the aminothiazole…

1
Expression of Cyclin D1 in Penile Cancer 3:36

1M ago3:36

3:36

BUFFALO, NY- May 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on May 14, 2024, entitled, “Cyclin D1 expression in penile cancer.”In this new study, researchers Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim…

1
Oncotarget at SSP 46th Annual Meeting 1:30

1M ago1:30

1:30

BUFFALO, NY- May 13, 2024 – BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.Impact Journals is proud to participate at the Society for Scholarly Publishing (SSP) 4…

1
SARS-CoV-2 Spike Protein Disrupts p53 Tumor Suppressor Pathway 9:24

1M ago9:24

9:24

The profound impact of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been felt across various domains, including the realm of cancer research and treatment. As scientists delve deeper into the intricate mechanisms of this viral pathogen, intriguing revelations have emerged regarding its potential influence on cellular processes pivotal…

1
Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction 3:42

1M ago3:42

3:42

BUFFALO, NY- May 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 7, 2024, entitled, “Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.”The sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation dosage. In this new …

1
Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy 4:01

1M ago4:01

4:01

BUFFALO, NY- May 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 3, 2024, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.”Severe acu…

1
Oncotarget Sponsors 19th International p53 Workshop in Italy 2:06

2M ago2:06

2:06

BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing #sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.“Groundbreaking research and cutting-edge advancements in the field of the most studied human g…

1
Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma 3:17

2M ago3:17

3:17

BUFFALO, NY- April 16, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.”The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated wi…

1
Synergistic Effects of Drug Combinations Targeting AML Cells 5:48

2M ago5:48

5:48

Acute myeloid leukemia (AML) is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. ABT199, also known as venetoclax, is a targeted therapy that inhibits the BCL-2 protein, which is often overexpressed in AML cells and contributes to the…

1
Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia 2:52

2M ago2:52

2:52

BUFFALO, NY- April 10, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the …

1
Identifying Biomarkers for Predicting Paclitaxel Response 5:48

3M ago5:48

5:48

Cancer therapy has come a long way from its one-size-fits-all beginning to the awakening era of personalized medicine. This change has been largely driven by the discovery of biomarkers. Biomarkers can help refine patient selection for specific therapies. A blend of causal and correlative approaches is needed to elucidate the full potential of biom…

1
Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer 3:15

3M ago3:15

3:15

BUFFALO, NY- March 27, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, …

1
ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells 3:21

3M ago3:21

3:21

BUFFALO, NY- March 25, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. Its effica…

1
Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal® 3:18

3M ago3:18

3:18

BUFFALO, NY- March 20, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke…

1
“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny 1:55

3M ago1:55

1:55

BUFFALO, NY- March 19, 2024 – A new #research perspective was #published by Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “From osimertinib to preemptive combinations.”“Here, I suggest that while first-line osimertinib extends median progression-free surviva…

1
A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation 3:32

3M ago3:32

3:32

BUFFALO, NY- March 18, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.”In this new study, researchers Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama Ghosh, Akanksha Mudgal, Divyesh Patel, Thenmala…

1
Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy 5:13

3M ago5:13

5:13

The relentless search for effective cancer therapies has led to numerous breakthroughs in drug discovery and development. Advancements have emerged in recent years through the promising avenue of combination therapy, where two or more drugs are used synergistically to enhance their collective therapeutic effect. This strategy has shown significant …

1
Oncotarget at AACR Annual Meeting 2024 1:31

3M ago1:31

1:31

BUFFALO, NY- March 11, 2024 – Impact Journals publishes #scholarly journals in the #biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) An…

1
GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells 3:38

3M ago3:38

3:38

BUFFALO, NY- March 6, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.”In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from Virginia Commonwealth University and Genzada Pharmaceu…

1
Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas 3:12

4M ago3:12

3:12

BUFFALO, NY- March 4, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.”Sacituzumab govitecan (SG) is an antibody-drug conjugat…

1
BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula 3:31

4M ago3:31

3:31

BUFFALO, NY- February 28, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.”In this new exploratory and descriptive study, researc…

1
GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells 3:32

4M ago3:32

3:32

BUFFALO, NY- February 26, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from Virginia Commonwealth University and G…

1
Raw Areca Nut Betel Quid Consumption and Esophageal Cancer 6:58

4M ago6:58

6:58

Betel quid chewing, a traditional custom widely practiced in South Asia, Southeast Asia, the Asia-Pacific region, and East Africa for centuries, involves the consumption of raw areca nut mixed with slaked lime and wrapped in a betel leaf. This habit is particularly popular in certain regions, including Northeast India, where the areca nut is raw, w…

1
Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel 2:28

4M ago2:28

2:28

BUFFALO, NY- February 21, 2024 – A new research #perspective was #published in Oncotarget's Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta, Adam M. Sonabend, …

1
NTRK Gene Fusion in Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland 3:07

4M ago3:07

3:07

BUFFALO, NY- February 19, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland.”Selective tropomyosin receptor kinase (TRK) inhibitors are approved targeted th…

1
Oncotarget’s Top 10 Papers Published in 2023 (Crossref Data) 5:26

4M ago5:26

5:26

Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved. Below are Crossref’s Top 10 Oncotarget DOIs published in 2023.10: Everolimus downregulates STAT3/HIF-1α/VEGF path…

1
Genetic and Therapeutic Landscapes in Cohort of Pancreatic Cancer Using NGS and Machine Learning 2:30

4M ago2:30

2:30

BUFFALO, NY- February 14, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.”About 7% of all cancer deaths are caused by pancreatic cancer (PCa)…

1
Differential Expression of Mad2 Gene in Human Esophageal Cancer 3:02

4M ago3:02

3:02

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples.”Raw areca nut (AN) consumption increases esophag…

1
Genetic Alterations in Thyroid Cancer: Resistance to BRAFi and Anaplastic Transformation 10:09

4M ago10:09

10:09

Thyroid cancer is a complex disease with various subtypes and clinical presentations. While some cases can be successfully treated with standard therapy, others present challenges due to resistance to treatment and the development of aggressive forms of the disease. In a new research perspective, researchers Mark Lee and Luc GT Morris from New York…

1
Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma 2:38

4M ago2:38

2:38

BUFFALO, NY- February 7, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Be…

1
Drug Discovery in Academia; Dumping in the Publication Landfill? 2:51

4M ago2:51

2:51

BUFFALO, NY- February 5, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?”In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Dev…

1
BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients 3:33

5M ago3:33

3:33

BUFFALO, NY- January 31, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.”Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-ar…

1
Gene Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition & Anaplastic Transformation 2:57

5M ago2:57

2:57

BUFFALO, NY- January 29, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.”In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memor…

1
New Drug May Boost Effectiveness of Glioblastoma Treatment 5:54

5M ago5:54

5:54

Glioblastoma is a type of brain cancer that is very aggressive and difficult to treat. The current standard treatment involves surgery, radiation therapy, and chemotherapy with a drug called temozolomide (TMZ). However, many glioblastoma cells can resist the DNA-damaging effects of TMZ and radiation by activating a mechanism called the DNA damage r…

1
Lazarus Effect in Patient Treated with Osimertinib for NSCLC with Leptomeningeal Disease 2:54

5M ago2:54

2:54

BUFFALO, NY- January 24, 2024 – A new #case report was #published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.”Osimertinib has been shown to be effective for patients wi…

1
Published in Oncoscience: My Battle with Cancer. Part 1. 1:41

5M ago1:41

1:41

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center #published a new brief #report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a m…

1
Bone Marrow Adipocytes Provide Early Sign of Progression from MGUS to Multiple Myeloma 3:22

5M ago3:22

3:22

BUFFALO, NY- January 22, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.”Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant p…

1
ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines 3:32

5M ago3:32

3:32

BUFFALO, NY- January 17, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on January 16, 2024, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.”Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) …

1
Reductive Carboxylation of Glutamine as a Potential Target in AML 1:55

5M ago1:55

1:55

BUFFALO, NY- January 16, 2024 – A new #editorial paper was #published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute…

1
How Osteopontin Stimulates Mitochondrial Biogenesis and Cancer Metastasis 6:23

5M ago6:23

6:23

Mitochondrial biogenesis, the process of increasing the size and number of mitochondria within cells, plays a crucial role in cancer metastasis. Metastasizing cells exhibit a unique metabolism that differs from the well-known Warburg effect observed in primary tumors. While primary tumors primarily rely on glycolysis for energy production, metastat…

1
One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers 2:18

5M ago2:18

2:18

BUFFALO, NY- January 10, 2024 – A new #editorial paper was #published in Oncotarget's Volume 14 on December 22, 2023, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.”Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted therapies …

1
Transformation-associated Recombination (TAR) Cloning and Its Applications 2:37

5M ago2:37

2:37

BUFFALO, NY- January 8, 2024 – A new #review paper was #published in Oncotarget's Volume 14 on December 22, 2023, entitled, “Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine.”Transformation-associated recombination (TAR) cloning represents …

Подкасты, которые стоит послушать

Подкасты на тему Oncotarget

Подкасты, которые стоит послушать

Краткое руководство